Compare Crispr Therapeutics AG (CRSP) vs Western Digital Corp (WDC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Western Digital Corp — how do they compare? Crispr Therapeutics AG trades at $53.8 (market cap $5.23B), while Western Digital Corp trades at $455.4 (market cap $150.95B). The key difference: Western Digital Corp is far larger — about 28.9× Crispr Therapeutics AG's market cap, and Western Digital Corp pays a 0.14% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | WDC | |
|---|---|---|
Market Cap | $5.23B | $150.95B |
Sector | Health | Technology |
52-Week High | $76.78 | $746.23 |
52-Week Low | $44.34 | $74.66 |
Enterprise Value | $3.65B | $150.42B |
Dividend Yield | — | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Western Digital (WDC) trades at $438.12, up 0.88% on the day, with strong recent earnings performance beating expectations for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 72.95% net income margin and 131.02% ROE. Recent news highlights AI-driven storage demand as a key growth catalyst, though the stock faces valuation concerns after recent sell-offs.
The outlook remains positive with 72% analyst buy ratings and $665 consensus price target, representing 52% upside potential. Key risks include stretched valuation metrics (P/E 18.04, EV/EBITDA 30.24) and competitive threats from SSD adoption. The company's strong AI storage positioning and margin expansion provide growth opportunities, but investors should monitor execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Western Digital Corp
Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →
